M. Andreas

Immunological dysfunction associated with SARS-CoV-2 persistence in immunocompromised patients

I. Johannsen, Line K. Vibholm, Giacomo S. Frattari, Míriam Rosás-Umbert et autres

Advances in coronavirus disease 2019 management has led to decreases in disease burden; however, immunocompromised patients continue to experience prolonged or persistent infections. We investigated immunological factors associated with time to viral clearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections …

dk, au, ru (code pays fourni par la source)

Vectored long-term co-delivery of antibodies for SARS-CoV-2, RSV and Influenza prophylaxis

Stine Sofie Frank Nielsen, Frederik Holm Rothemejer, M. Andreas, Maria Lange Pedersen et autres

dk, us (code pays fourni par la source)

Exploring the Immunological Factors Impacting SARS-CoV-2 Persistence in Patients with Secondary Immunodeficiencies

Line K. Vibholm, Giacomo S. Frattari, Míriam Rosás-Umbert, Irene Harder Tarpgaard et autres

dk (code pays fourni par la source)

POS0007 KYV-101, A FULLY HUMAN CD19 CAR T CELL GENERATED FROM AUTOIMMUNE PATIENT LYMPHOCYTES, DEMONSTRATES CAR-MEDIATED AND CD19-DEPENDENT ACTIVITY AGAINST AUTOLOGOUS B CELLS

Sungha Park, Ames C. Register, H. Y. Lee, Gloria Lutzny‐Geier et autres

de (code pays fourni par la source)

OP0141 LONG TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS - DATA FROM THE FIRST SEVEN PATIENTS

J. Taubmann, Fabian Müller, Sebastian Boeltz, Simon Völkl et autres

de, cn, it (code pays fourni par la source)

AB0816 TREATMENT OF A PATIENT WITH SEVERE DIFFUSE SYSTEMIC SCLEROSIS (SSC) USING CD19-TARGETING CAR-T-CELLS

Christina Bergmann, Fabian Müller, David J. Jörg, D. M. H. Györfi et autres

de (code pays fourni par la source)

POS1238 FIRST EVIDENCE FOR EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY ANTISYNTHETASE SYNDROME

J. Taubmann, Fabian Müller, Sebastian Boeltz, Johannes Knitza et autres

de, be, it, jp (code pays fourni par la source)

OP0279 CAR-T CELL TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS- SAFETY AND PRELIMINARY EFFICACY DATA FROM THE FIRST FOUR PATIENTS

Georg Schett, S. Boeltz, F. Müller, A. Kleyer et autres

de (code pays fourni par la source)